Expression profile of Twist, vascular endothelial growth factor and CD34 in patients with different phases of osteosarcoma

Lei,Pengfei; Ding,Dengfeng; Xie,Jie; Wang,Long; Liao,Qiande; Hu,Yihe

doi:10.3892/ol.2015.3246

Expression profile of Twist, vascular endothelial growth factor and CD34 in patients with different phases of osteosarcoma

Authors:
- Pengfei Lei
- Dengfeng Ding
- Jie Xie
- Long Wang
- Qiande Liao
- Yihe Hu
View Affiliations

Affiliations: Department of Orthopedics, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China
Published online on: May 20, 2015 https://doi.org/10.3892/ol.2015.3246
Pages: 417-421

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the clinical significance of Twist, vascular endothelial growth factor (VEGF) and CD34 expression in osteosarcoma (OS) in order to elucidate potential therapeutic targets for the treatment of OS. Immunohistochemistry was performed to detect the protein expression of Twist, VEGF and CD34 in OS and osteochondroma (OC) tissues. The ratio of the protein expression of Twist and VEGF in OS and OC tissues as well as at different phases of OS was compared using chi‑squared tests. Microvessel density (MVD), as determined by CD34 labeling, in OS and OC tissue as well as at different phases of OS was compared using the Student's t‑test. In addition, associations between Twist, VEGF and MVD were assessed using the Spearman's rank correlation test. The results revealed that out of the 32 OS tissues examined, 56.25% exhibited Twist positive expression, 71.88% exhibited VEGF positive expression and the MVD was increased compared with that of the OC tissue. The positive rate of Twist and VEGF expression in phase III OS tissues was significantly increased compared with that in phase I/II OS tissues (Twist: χ2=5.732, P=0.018; VEGF: χ2=7.513, P=0.006). The MVD in phase III OS tissues (31.08±3.36 per field) was significantly higher compared with that of the phase I/II OS tissues (41.2±4.17 per field; t=7.536, P<0.001). Spearman's rank correlation analysis revealed that Twist expression was positively associated with VEGF expression (r=0.371, P=0.002) and with MVD (r=0.393, P=0.001) in OS; in addition, VEGF expression was found to have a positive correlation with MVD (r=0.469, P=0.001). In conclusion, the results of the present study demonstrated that OS tissues exhibited elevated Twist and VEGF expression as well as MVD compared with OC tissue. In addition, metastatic OS (phase III) exhibited an increased positive rate of Twist and VEGF expression as well as MVD values compared with non‑metastatic OS (phase I/II). Furthermore associations were detected between Twist and VEGF expression as well as VEGF and MVD. Therefore, inhibition of Twist expression may have potential therapeutic use for the treatment of OS.

View Figures

View References

1	Yin K, Liao Q, He H and Zhong D: Prognostic value of Twist and E-cadherin in patients with osteosarcoma. Med Oncol. 29:3449–3455. 2012. View Article : Google Scholar : PubMed/NCBI
2	Mullen JT, Hornicek FJ, Harmon DC, et al: Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. Cancer. 120:3676–3682. 2014. View Article : Google Scholar : PubMed/NCBI
3	Zhou Y, Zang X, Huang Z and Zhang C: TWIST interacts with endothelin-1/endothelin A receptor signaling in osteosarcoma cell survival against cisplatin. Oncol Lett. 5:857–861. 2013.PubMed/NCBI
4	Levens D and Larson DR: A new twist on transcriptional bursting. Cell. 158:241–242. 2014. View Article : Google Scholar : PubMed/NCBI
5	Khan MA, Chen HC, Zhang D and Fu J: Twist: A molecular target in cancer therapeutics. Tumour Biol. 34:2497–2506. 2013. View Article : Google Scholar : PubMed/NCBI
6	Mironchik Y, Winnard PT Jr, Vesuna F, et al: Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res. 65:10801–10809. 2005. View Article : Google Scholar : PubMed/NCBI
7	Niu RF, Zhang L, Xi GM, et al: Up-regulation of Twist induces angiogenesis and correlates with metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res. 26:385–394. 2007.PubMed/NCBI
8	Wallerand H, Robert G, Pasticier G, et al: The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol. 28:473–479. 2010. View Article : Google Scholar : PubMed/NCBI
9	Sossey-Alaoui K, Pluskota E, Davuluri G, et al: Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis. FASEB J. 28:2260–2271. 2014. View Article : Google Scholar : PubMed/NCBI
10	Low-Marchelli JM, Ardi VC, Vizcarra EA, van Rooijen N, Quigley JP and Yang J: Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res. 73:662–671. 2013. View Article : Google Scholar : PubMed/NCBI
11	Tanaka T, Yui Y, Naka N, et al: Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy. Clin Exp Metastasis. 30:369–379. 2013. View Article : Google Scholar : PubMed/NCBI
12	Sakurai T, Okumura H, Matsumoto M, et al: Endoglin (CD105) is a useful marker for evaluating microvessel density and predicting prognosis in esophageal squamous cell carcinoma. Anticancer Res. 34:3431–3438. 2014.PubMed/NCBI
13	Wang WQ, Liu L, Xu HX, et al: The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. Oncotarget. 5:3895–3906. 2014.PubMed/NCBI
14	Ek ET, Ojaimi J, Kitagawa Y and Choong PF: Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma. Oncol Rep. 16:17–23. 2006.PubMed/NCBI
15	He S, Xiao Z, Chen L and Xiong S: Comment on, Xu XW, et al: Prognostic significance of VEGF expression in osteosarcoma: A meta-analysis. Tumour Biol. 35:6193–6194. 2014. View Article : Google Scholar : PubMed/NCBI
16	Becker RG, Galia CR, Morini S and Viana CR: Immunohistochemical expression of vegf and her-2 proteins in osteosarcoma biopsies. Acta Ortop Bras. 21:233–238. 2013. View Article : Google Scholar : PubMed/NCBI
17	Ohba T, Cates JM, Cole HA, et al: Autocrine VEGF/VEGFR1 signaling in a subpopulation of cells associates with aggressive osteosarcoma. Mol Cancer Res. 12:1100–1111. 2014. View Article : Google Scholar : PubMed/NCBI
18	Roberts CC, Daffner RH, Weissman BN, et al: ACR appropriateness criteria on metastatic bone disease. J Am Coll Radiol. 7:400–409. 2010. View Article : Google Scholar : PubMed/NCBI
19	Zhou W, Hao M, Du X, Chen K, Wang G and Yang J: Advances in targeted therapy for osteosarcoma. Discov Med. 17:301–307. 2014.PubMed/NCBI
20	Rettew AN, Getty PJ and Greenfield EM: Receptor tyrosine kinases in osteosarcoma: not just the usual suspects. Adv Exp Med Biol. 804:47–66. 2014.PubMed/NCBI
21	Ohba K, Miyata Y, Matsuo T, et al: High expression of Twist is associated with tumor aggressiveness and poor prognosis in patients with renal cell carcinoma. Int J Clin Exp Pathol. 7:3158–3165. 2014.PubMed/NCBI
22	Galvan JA, Helbling M, Koelzer VH, et al: TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget. 6:874–885. 2015.PubMed/NCBI
23	Wang T, Li Y, Wang W, et al: Twist2, the key Twist isoform related to prognosis, promotes invasion of cervical cancer by inducing epithelial-mesenchymal transition and blocking senescence. Hum Pathol. 45:1839–1846. 2014. View Article : Google Scholar : PubMed/NCBI
24	Wang T, Li Y, Tuerhanjiang A, et al: Twist2 contributes to cisplatin-resistance of ovarian cancer through the AKT/GSK-3beta signaling pathway. Oncol Lett. 7:1102–1108. 2014.PubMed/NCBI
25	Wang SW, Liu SC, Sun HL, et al: CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment. Carcinogenesis. 36:104–114. 2015. View Article : Google Scholar : PubMed/NCBI
26	Yu XW, Wu TY, Yi X, et al: Prognostic significance of VEGF expression in osteosarcoma: A meta-analysis. Tumour Biol. 35:155–160. 2014. View Article : Google Scholar : PubMed/NCBI
27	Zhou Q, Zhu Y, Deng Z, Long H, Zhang S and Chen X: VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol. 20:13–19. 2011. View Article : Google Scholar : PubMed/NCBI
28	Chen D, Zhang YJ, Zhu KW and Wang WC: A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumour Biol. 34:1895–1899. 2013. View Article : Google Scholar : PubMed/NCBI
29	Lu SM, Yu L, Tian JJ, et al: Twist modulates lymphangiogenesis and correlates with lymph node metastasis in supraglottic carcinoma. Chin Med J (Engl). 124:1483–1487. 2011.PubMed/NCBI
30	Che N, Zhao XL, Sun T, et al: The role of Twist1 in hepatocellular carcinoma angiogenesis: A clinical study. Hum Pathol. 42:840–847. 2011. View Article : Google Scholar : PubMed/NCBI
31	Dalal S, Berry AM, Cullinane CJ, et al: Vascular endothelial growth factor: A therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res. 11:2364–2378. 2005. View Article : Google Scholar : PubMed/NCBI
32	Kaya M, Wada T, Kawaguchi S, et al: Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer. 86:864–869. 2002. View Article : Google Scholar : PubMed/NCBI
33	Oda Y, Yamamoto H, Tamiya S, et al: CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: Analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol. 19:738–745. 2006. View Article : Google Scholar : PubMed/NCBI